Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.58
- Piotroski Score 1.00
- Grade Buy
- Symbol (LSTA)
- Company Lisata Therapeutics, Inc.
- Price $2.71
- Changes Percentage (-4.13%)
- Change -$0.12
- Day Low $2.70
- Day High $2.80
- Year High $3.83
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 10/28/2013
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.46
- Trailing P/E Ratio -1.33
- Forward P/E Ratio -1.33
- P/E Growth -1.33
- Net Income $-20,840,000
Income Statement
Quarterly
Annual
Latest News of LSTA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Apple ups satellite investment stakes with latest Globalstar deal
Apple's $1.5bn deal with Globalstar in 2024 for LEO satellite services positions it as a leader in satellite connectivity. This move challenges carriers' D2D satellite efforts and sets Apple apart in ...
By Yahoo! Finance | 18 hours ago -
LocalStack raises $25M to help developers emulate and test cloud apps locally | TechCrunch
LocalStack, a Swiss startup, aims to streamline cloud application development by enabling developers to emulate the cloud environment on their local machines. With a recent $25 million Series A fundin...
By TechCrunch | 6 days ago -
The Allstate Corporation (ALL): Navigating Catastrophe Losses and Strategic Turnarounds
Tech stocks have outperformed real estate and biotech, with information technology stocks surging by 115%, driven by AI advancements. UBS predicts US tech sector to be 'Most Attractive' due to AI....
By Yahoo! Finance | 6 days ago
